Scimeca Dario 4

What Happened

• Dario Scimeca, General Counsel and Secretary of Precision BioSciences (DTIL), had Restricted Stock Units (RSUs) vest on Feb 17, 2026. The vesting resulted in the conversion/acquisition of 16,667 shares (reported as an exercise/conversion at $0.00).
• Following the vesting, 4,925 of those shares were sold in an open-market transaction on Feb 18, 2026 at $3.84 per share, generating $18,912. The remaining shares from this vesting installment (16,667 − 4,925 = 11,742) were retained.
• The reported disposal of 16,667 derivative units at $0.00 reflects the settlement/conversion of the RSUs into common stock.

Key Details

• Transaction dates/prices: 02/17/2026 conversion of 16,667 RSUs → 16,667 shares at $0.00; 02/18/2026 sale of 4,925 shares at $3.84 ($18,912).
• Net from this vesting: +11,742 shares retained after the sell-to-cover.
• Footnotes: RSUs vested on 02/17/2026 (each RSU = one share). The sale was a sell-to-cover executed under a Rule 10b5-1 plan adopted 09/29/2025; only shares needed to satisfy tax withholding were sold.
• Filing/timeliness: Period of report 02/17/2026; Form 4 filed 02/19/2026 — appears timely (Form 4 is generally due within two business days).

Context

• This was a routine vesting and sell-to-cover to satisfy tax withholding; such sales are common and do not necessarily signal a change in insider sentiment. The key actionable item is that Scimeca retained the majority of the vested shares from this installment.